Health news
Health news top Health news

   Login  |  Register    
Health News Make AMN Your Home PageDiscussion BoardsAdvanced Search ToolMedical RSS/XML News FeedHealth news
  You are here : Health.am > Health Centers > Eye / Vision Problems - Genetics -
Gene therapy sets stage for new treatments for inherited blindness, Penn veterinary researchers say Gene therapy sets stage for new treatments for inherited blindness, Penn veterinary researchers say

Gene therapy sets stage for new treatments for inherited blindness, Penn veterinary researchers say

Eye / Vision Problems • • GeneticsApr 29, 2010

Veterinary vision scientists at the University of Pennsylvania have safely and successfully used a viral vector in targeting a class of photoreceptors of the retina called rods, a critical first step in developing gene therapies for inherited blindness caused by rod degeneration.

In this study, the viral vector, or missile that carries the genetic material designed to correct a DNA mutation, was not intended to treat a disease but to demonstrate through the use of a fluorescent protein that a safe and effective viral cocktail could be delivered inside rod cells.

The next major challenge that vision researchers face is to target these photoreceptor cells for treatment, as the majority of retinal degenerative diseases are caused by mutations that damage these cells. Photoreceptors are the cells in the retina responsible for capturing light and transforming it into an electrical signal that will be interpreted by the brain. 

A consortium of researchers from Penn and the University of Florida used a specific adeno-associated virus, AAV2/5, to carry the gene of a green fluorescent protein. The scientists tested whether three different promoters, pieces of DNA that play the role of a switch, could turn on the production of the green fluorescent protein in rods in dogs. Two of the three viral cocktails were able to turn on the production of the green fluorescent protein specifically in rods, while the third viral cocktail targeted rods, cones and other retinal cells; however only the proper concentration of each viral vector proved to be just right. Efficient and specific rod transduction, together with preservation of retinal structure, was achieved with both mOP and hGRK1 promoters when viral titers in the order of 1011 vg/ml were used.

“Now that we’ve demonstrated this type of delivery can be accomplished, “ said William A. Beltran, assistant professor of ophthalmology at Penn’s School of Veterinary Medicine and director of the study, “the next step is to target common rod degenerations using canine models that mimic the human diseases. The delivery of a viral vector, coupled with a rod-specific promoter is likely to be the safest and most efficient approach to correct diseases such as X-linked and autosomal dominant retinitis pigmentosa, both of which lead to complete blindness.”

A form of childhood blindness called RPE65-Leber’s congenital amaurosis, LCA, is the first — and to this date the only — inherited retinal disease for which corrective gene therapy is currently being tested in three on-going clinical trials. This treatment was first developed and perfected in dogs by some of the scientists who participated in the present study before its use in human patients.

The study appears in the current issue of the Journal of Gene Therapy.

###

Research was conducted by Beltran and Gustavo D. Aguirre of the Department of Clinical Studies at Penn Vet and Sanford L. Boye, Shannon E. Boye, Vince A. Chiodo and William W. Hauswirth of the Department of Ophthalmology and Alfred S. Lewin of the Department of Molecular Genetics and Microbiology, all at UF.

Hauswirth and the University of Florida have a financial interest in the use of rAAV therapies and own equity in AGTC Inc. All remaining authors declare that they have no competing financial interests.

This work was supported by grants from the National Institutes of Health, The Foundation Fighting Blindness, Fight for Sight, the Hope for Vision Foundation and the ONCE International Price for R&D in Biomedicine and New Technologies for the Blind.

---
Contact: Jordan Reese

215-573-6604
University of Pennsylvania

Provided by ArmMed Media

Gene therapy sets stage for new treatments for inherited blindness, Penn veterinary researchers say Bookmark this! Gene therapy sets stage for new treatments for inherited blindness, Penn veterinary researchers say

RELATED STORIES:


 Comments [ + Post Your Own

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]




We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.

All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

Please enter the word you see in the image below:


   [advanced search]   
What health info have you recently searched for online?
Disease or condition
Exercise or fitness
Diet, nutrition or vitamins
None of the above


Get free support - Headache Causes, Symptoms, Diagnosis, and Treatment on HeadacheCare.net


Health Centers







Diabetes

















Health news
  


Health Encyclopedia

Diseases & Conditions

Drugs & Medications

Health Tools

Health Tools



   Health newsletter

  





   Medical Links



   RSS/XML News Feed



   Feedback


Add to Yahoo RSS News Feed



Google Reader




Syndicate


This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
Verify here.




HIV-AID. HIV Express Test Kit